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A B S T R A C T
This review highlights how hydrogel formulations can improve intravitreal protein delivery to the posterior
segment of the eye in order to increase therapeutic outcome and patient compliance. Several therapeutic pro-
teins have shown excellent clinical successes for the treatment of various intraocular diseases. However, drug
delivery to the posterior segment of the eye faces significant challenges due to multiple physiological barriers
preventing drugs from reaching the retina, among which intravitreal protein instability and rapid clearance from
the site of injection. Hence, frequent injections are required to maintain therapeutic levels. Moreover, because
the world population ages, the number of patients suffering from ocular diseases, such as age-related macular
degeneration (AMD) and diabetic retinopathy (DR) is increasing and causing increased health care costs.
Therefore, there is a growing need for suitable delivery systems able to tackle the current limitations in retinal
protein delivery, which also may reduce costs. Hydrogels have shown to be promising delivery systems capable
of sustaining release of therapeutic proteins and thus extending their local presence. Here, an extensive overview
of preclinically developed intravitreal hydrogels is provided with attention to the rational design of clinically
useful intravitreal systems. The currently used polymers, crosslinking mechanisms, in vitro/in vivo models and
advancements are discussed together with the limitations and future perspective of these biomaterials.
1. Introduction
Drug delivery to intraocular tissues is one of the major challenges
faced by ophthalmologists and formulation scientists because the eye is
a highly complex, isolated and specialized organ of the human body.
The challenge of drug delivery to this organ is related to the presence of
different barriers that prevent exogenous and harmful substances from
entering the posterior chamber, in particular, the retina and optic
nerve. Vision-threatening disorders are mostly related to abnormalities
in intraocular tissues, especially in the retina. The occurrence of such
diseases is rapidly increasing in industrialized countries, not only in the
ageing populations but also in younger individuals, causing a sub-
stantial health problem in modern society. It is estimated that ap-
proximately 285 million people worldwide are visually impaired, and
39 million are completely blind.[1,2] These numbers are expected to
double by 2050, representing a significant public health burden.[3,4]
Conventional eye drops containing low molecular weight drugs are
the most commonly used ophthalmic drug formulations. Although they
are not suitable for the delivery of therapeutic proteins, they represent
90% of the ocular products present in the market, which is due to ease
of manufacturing and scale-up, stability and cost-effectiveness[5].
However, after topical instillation into the lacrimal fluid, drugs are
rapidly removed from the ocular surface due to solution drainage and
systemic drug absorption across the conjunctiva that lines the inner side
of eyelids. Furthermore, the epithelia of the cornea and bulbar con-
junctiva are major barriers for drug absorption into the eye. Therefore,
only a minimal amount (< 5%) of the administered drug dose reaches
the anterior part of the eye, and even a much smaller fraction
(< <1%) reaches the posterior eye segment after topical administra-
tion of the drug formulations.[6,7]. Thus, frequent administration is
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needed to maintain drug concentrations within the therapeutic
window.[4,8]
A wide range of posterior segment eye pathologies severely impacts
vision. These disorders include neovascular age-related macular de-
generation (AMD), diabetic retinopathy (DR), diabetic macular edema
(DME), retinal vein occlusions (RVO) and diseases that originate from
the alteration in the vasculature system of the retina, genetic disorders
and eye tumours[9,10]. Many studies have demonstrated that vascular
endothelial growth factor (VEGF) plays a crucial role in the patho-
genesis of retinal diseases.[11,12] Therefore, many therapeutic ap-
proaches aim at blocking VEGF signalling by the delivery of in-
travitreally injected anti-VEGF proteins.[13,14] The effectiveness of
antibodies (bevacizumab, Avastin®), antibody fragments (ranibizumab,
Lucentis®), and soluble receptors (aflibercept, Eylea®) have been shown
in the treatment of patients with neovascular AMD.[15] However,
maintaining sufficient concentrations in the retina after intravitreal
injection for an extended period is an important challenge. Monthly
injections are burdensome and have resulted in impaired patient com-
pliance[16,17].
In the past decades, tremendous efforts have been made to improve
the disposition of drugs, especially bioactive proteins, in the retina by
using different routes of administration and drug delivery vehicles.
Several drug delivery technologies such as in-situ forming hydrogels,
micelles, liposomes, nanoparticles and ocular implants have been de-
veloped for ocular applications.[18,19] In-situ forming hydrogels are
considered attractive biomaterials, which can be engineered to offer
several benefits, including less frequent administrations, patient com-
fort and cost reduction. Furthermore, hydrogels that jellify in-situ allow
loading of therapeutically active compounds during network formation
facilitating local delivery and release through a minimally invasive
procedure. In the past years, the use of hydrogels have received in-
creased attention as ophthalmic formulations that deliver drugs to the
posterior segments.[20–24]
This present review discusses and highlights the clinical success of
therapeutic proteins in the treatments for posterior eye diseases and the
major limitations in protein delivery to the posterior segment of the
eye. Anatomical and physiological barriers in ocular protein delivery
are summarized and discussed. It is further conferred how in-situ
forming hydrogels can improve the long-term release and subsequent
exposure of protein-based therapeutics to the posterior segment of the
eye, especially to the retina. Different, biodegradable, natural and
synthetic hydrogels are presented together with diverse functional
groups and crosslinking mechanisms employed to obtain hydrogels
with suitable drug release profiles. Guidance on the rational design of
ideal drug delivery systems to the posterior segment of the eye is pro-
vided in addition to the critical issues related to these delivery tech-
nologies.
2. Drug administration to the posterior segment of the eye
2.1. Anatomical and physiological components of the eye
The eye is a highly complex, isolated and specialized organ of the
human body. The structure can be classified into two segments: anterior
and posterior. The main structures in the anterior chamber are the
cornea, conjunctiva, iris, ciliary body, aqueous humour, lens and sup-
porting structures. The posterior chamber encompasses the sclera,
choroid, retina, and vitreous body (Fig. 1). The vitreous cavity contains
the vitreous body, which is a transparent, gelatinous mass located be-
tween the lens and the retina. The vitreous humour body is a highly
hydrated three-dimensional network of hyaluronic acid (HA) ~0.5%
and collagen ~0.5% with a water content of ~99%.[25,26] In order to
perceive and recognize objects, light passes through the anterior
chamber to the posterior chamber. Light ‘travels’ the eye through the
cornea, the pupil and hits the lens, a convex and transparent disc that
focuses and projects the light onto the retina, which is located in the
inner layer of the back of the eyeball. The retina is loaded with millions
of photoreceptors, which convert light energy into electrical signals
that, in turn, the brain receives as impulses to produce images. Drug
delivery to the retina can be achieved by various routes such as topical,
systemic, intravitreal, sub-retinal, subconjunctival, intracameral and
periocular administration. Unfortunately, most patient-friendly ad-
ministration routes, among which topical and systemic, often result in
poor drug bioavailability. Drugs administered to the eye can be re-
stricted by various static and dynamic barriers, as discussed in section
2.2. Particularly, conventional formulations are unable to efficiently
deliver proteins into the eye owing to these complex barriers and
elimination mechanisms. Therefore, intravitreal injectable depot for-
mulations may solve these limitations by bypassing these barriers and
providing a sustained release of proteins reaching intraocular tissues.
2.2. Anatomical and physiological barriers in ocular drug delivery
In-depth knowledge of ocular barriers and pharmacokinetics is es-
sential for the development of effective delivery technologies to the
retina. Generally, two types of barriers can be distinguished: 1) ana-
tomical/static barriers representing the different layers of cornea,
sclera, conjunctiva, and retina blood-aqueous and blood-retinal bar-
riers. 2) physiological/dynamic barriers including choroidal and con-
junctival blood flow, lymphatic clearance, efflux transport, nasola-
crimal drainage and tear turnover.
2.2.1. Topical administration
Topically administered eye drops are frequently used to treat
anterior segment diseases therapeutically. However, this mode of drug
administration is associated with low ocular bioavailability due to dy-
namic and anatomical barriers.[7] After installation to the eye, the
solution drainage in tears and eye blinking results in rapid precorneal
drug loss into the nasolacrimal duct, leading to poor absorption of small
molecules (< 5%) even into the anterior eye tissues. Importantly,
protein drugs have negligible absorption to the anterior eye tissues after
topical administration.[22,27] Most of the dose of small molecular
drugs after topical administration is absorbed into the systemic circu-
lation via the highly vascularized nasolacrimal duct, which in turn can
result in adverse systemic effects.[5,28–30] Depending on the drug and
the technique of application to the ocular surface, these adverse effects
encompasses low blood pressure, reduced heart pulse rate, fatigue,
shortness of breath, headaches, allergic reactions and many more.[31]
The delivery of topically applied drugs to the posterior eye segment is
1-2 orders of magnitude lower than to the anterior segment due to
several reasons.[7,32] Firstly, the flow of aqueous humor from the
posterior to the anterior chamber limits drug access to the intravitreal
cavity.23,[33,34] Also, systemic drug distribution from aqueous humor to
the blood circulation of the iris and ciliary body reduces distribution to
the posterior eye segment.[7] Finally, the lens forms a dense barrier
that limits drug penetration.[35]
2.2.2. Systemic administration
In ophthalmic therapy, systemic administration has been used to
deliver antibodies, antibiotics and carbonic anhydrase inhibitors to
treat various diseases like endophthalmitis, elevated intraocular pres-
sure and uveitis.[29,36–38] The presence of the blood-retinal barrier
(BRB) regulates the transfer of drugs from the blood circulation to the
eye in both directions and can be a major limiting barrier. The blood-
ocular barriers consist of a posterior BRB and an anterior blood-aqueous
barrier (BAB), and together they represent an impenetrable tight barrier
for proteins and other macromolecular therapeutics larger than 2 nm in
diameter.[7] The BAB is formed by the inner non-pigmented ciliary
epithelium, ciliary muscle capillaries and posterior iris epithelium. The
BRB is made up of retinal pigment epithelium (RPE) and inner retinal
endothelial capillaries (inner BRB). The RPE is a tight cellular mono-
layer that is located between the photoreceptors and choroid.[39] It
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regulates the homeostasis of the neural retina and the outer part of the
BRB by controlling, e.g. epithelial transport, secretion, phagocytosis,
spatial ion buffering and immune modulation.[40] It is, however,
challenging to quantify the permeability of BAB and BRB separately
because, after intravitreal injection or intravenous administration, as
drugs can be eliminated from the eye through both of these barriers.
[41] Furthermore, because of these physiological barriers, high drug
doses and repetitive administration are necessary to achieve adequate
therapeutic drug levels with the risk of adverse off-target effects.[42]
2.2.3. Intravitreal administration (IVT)
In clinics, intravitreal drug delivery is the only successful route of
administration for proteinaceous drugs (such as anti-VEGF compounds)
to the posterior segment of the eye, because of the proximity of the
vitreous to the retina.[27,43–45] Intravitreal administration results in
high retinal bioavailability since the drug is directly injected into the
vitreous in the vicinity of the retina. After intravitreal injection, protein
drugs distribute by Fickian diffusion from the vitreous over the sur-
rounding ocular tissues, reaching the target sites in the retina.[7] The
vitreous body does not act as a severe barrier for the diffusion of soluble
proteins. However, it might limit the mobility of the administered de-
livery systems (e.g. drug-loaded nanoparticles) depending on their
physico-chemical properties and design to deliver proteins to the pos-
terior segment.[46] As mentioned before, one of the main components
of the vitreous body, besides water, is hyaluronic acid, a hydrophilic
polysaccharide with a molecular weight up to 2-3*106 Da.[7,47] The
vitreous humour has a loose and open structure that allows rapid dif-
fusion of low molecular weight drug molecules since the mesh size in
the vitreous network has been estimated to be ~500 nm.[7,48,49]
Biologics generally administered through intravitreal injections do not
exceed a diameter of 10 nm, e.g. bevacizumab (6.5 nm) and ranibi-
zumab (4.1 nm), and therefore based on size only they should not
display restricted mobility in the vitreous.[47,50] The diffusion of ag-
gregates of self-assembled polymers, and nanoparticulate carriers can
be restricted.[51] Additionally, positively charged molecules and par-
ticles can also be restricted because these cationic entities can bind to
the negatively charged hyaluronic acid matrix.[52] Importantly, the
movement of macroscopic hydrogels, microspheres and drug-loaded
implants are significantly restricted or even absent in the vitreous as
they are bigger than the average mesh size in the vitreous network of
hyaluronic acid (500 nm). These systems can, therefore, be used as
localized reservoirs for sustained drug delivery to the retina. Drug
elimination from the vitreous cavity takes place either via anterior or
posterior clearance. The anterior route involves drug diffusion in the
vitreous to the posterior chamber, followed by convective elimination
in the aqueous humor outflow.[33,53,54] The posterior route involves
drug diffusion to the retina, followed by permeation across the blood-
retina barriers into the systemic blood circulation.[33,55],40 Pharma-
cokinetic studies suggest that intravitreally administered biologicals are
mostly eliminated from the eye by the anterior route, while a smaller
fraction of the dose (≈10%) escapes across the blood-retina barrier.41
The posterior clearance is only relevant for therapeutic compounds
that can cross the endothelial and epithelial of blood-ocular barriers
(typically only small molecular drugs).[55] These barriers are selective,
allowing passage of small molecules with lipophilic properties (smaller
than 2 nm in diameter) while restricting the permeation of large mo-
lecules.[7] For this reason, the half-lives of low molecular weight mo-
lecules in the vitreous are typically in the range of 1-10 h, while those of
proteins and other macromolecules are in the range of several days.[55]
Unfortunately, ocular intravitreal therapies of therapeutic proteins
presently applied in the clinics are associated with serious risks due to
their frequent injections. This recurrence results in an increased risk of
hemorrhage, retinal detachment, persistent discomfort, degeneration of
photoreceptors (PRs), cataract formation, bacterial endophthalmitis
and increased intraocular pressure (IOP).[7] New delivery systems are,
therefore, urgently needed to prolong the injection intervals for im-
proved treatments of retinal diseases and to reduce side effects. Parti-
cularly, tolerability and biocompatibility issues, biodegradability,
sterility, reproducible manufacturing and eventually preclinical and
clinical performance must be taken into consideration when developing
such delivery systems for clinical translation.
2.2.4. Other administration strategies
Besides topical, systemic and IVT administration, some of the most
actively investigated routes to bypass barrier functions in the eye and
promote localization of drugs to the back of the eye are periocular,
Fig. 1. Anatomical components of the eye and frequently used routes of drug administration.
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subretinal, intrascleral and suprachoroidal routes.[56–58] Drug and
gene delivery through each of these routes of administration can be
limited by various static/dynamic barriers, as discussed by del Amo
et al.[7] and Rowe-Rendleman et al.[59] Briefly, depending on the
exact location, drug diffusion to the posterior segment after injections
of drug formulations can be limited by static barriers such as sclera,
choroid, Bruch's membrane, RPE tight junctions and retina. At the same
time, dynamic restrictions can include choroidal circulation, retinal
circulation, subconjunctival-episcleral lymph and blood vessels.
[60–62] Despite these limiting barriers, many innovative drug delivery
systems and strategies (such as nanoparticles, hydrogels, dendrimers,
adenovirus, microspheres and microneedles) are being investigated in
animal studies and clinical trials using periocular, subretinal, in-
trascleral, and suprachoroidal routes of administration.[46,63–67]
Minimally invasive microneedle-based ocular delivery is worth
mentioning as it has the potential to revolutionize the way drug for-
mulations are administered within ocular tissues. Solid and hollow
microneedles were initially developed for drug delivery to the skin,
where they are used to form micron-sized pores on body surfaces
through which drugs can directly enter tissue layers and therefore in-
crease drug permeation. In recent years this technology has been de-
signed to be applied on the ocular surface (e.g. cornea, sclera and su-
prachoroidal space) to treat diseases in the anterior and posterior
segments avoiding complications associated with ocular injections with
conventional needles as discussed by Thakur Singh et al.[68] Im-
portantly, this delivery strategy can significantly minimize damage to
the ocular tissues, reduce patient discomfort/pain due to its micron-
sized needle (typically 25-2000 μm in height) and allow precise loca-
lization of drug formulations, as shown by Park et al.[69] and Song
et al.[70] Microneedles have been used together with drug delivery
systems (e.g. gel formulations, nanoparticle and microparticle suspen-
sion) for sustained delivery.[71,72] The delivery of low molecular
weight drugs via microneedles to the anterior segment and the posterior
segment has been extensively investigated.[69,70,72] While delivery of
therapeutic proteins has been developed primarily for the anterior
segment, especially in the treatment of corneal neovascularization with
limited information about the treatment of posterior eye diseases.
[63,73] Furthermore, it is essential to note that drug distribution to the
posterior segment after intrascleral or suprachoroidal microneedle in-
jection can still be limited by the previously mentioned barriers. Issues
concerning forces of injection, IOP, method of injection/retraction and
the overall safety of the technology are to be systematically studied
together with long term delivery of therapeutic proteins to examine the
full benefits of microneedles for ocular applications.[68]
2.3. Clinical success of therapeutic proteins for intraocular diseases
During the last decade, the market of ophthalmic biologicals such as
monoclonal antibodies, peptides, aptamers and recombinant proteins
has been growing enormously. In 2017, the worldwide sales of mono-
clonal antibodies for various biomedical applications were estimated to
be over 98 billion US$.[74] The success of these biologicals became
possible due to the tremendous advances in the fields of genetic en-
gineering, innovative biotechnology, pharmaceutics, identification of
druggable targets, formulation and GMP production.[75,76] Particu-
larly, attention has been given to the pharmaceutical development of
anti-VEGF agents to rescue vision in retinal vascular diseases after the
validation of the importance of the elevated intraocular levels of vas-
cular endothelial growth factor (VEGF-A). These growth factors are
responsible for the angiogenesis and neovascularization in the retina
and, therefore, involved in the modulation of posterior segment eye
diseases. These diseases include age-related macular degeneration
(AMD), diabetic retinopathy (DR),[77] retinal vein occlusion with cy-
stoid macular edema (CME), posterior uveitis.[78] AMD and DR are the
leading causes of visual impairment worldwide.[1] The prevalence of
these diseases is likely to increase with the rapid growth of the ageing
population representing a major public health burden.[1,79]
AMD is an abnormality of the retinal pigment epithelium (RPE) that
leads to the degeneration of the photoreceptors in the macula and
consequent loss of central vision in elderly individuals. There are two
main forms of AMD: neovascular (wet) and non-neovascular (dry),
which affect over 16 million people in Europe and the United States.
[80] The wet form represents 90% of cases of severe sight loss in AMD
patients and usually affects both eyes. Wet AMD is known as abnormal
neovascularization in the central region of the retina.[79] This ab-
normality results in vision loss due to retinal damage caused by fluid
leakage and scar formation. The global cost of wet age-related macular
degeneration (AMD) market is estimated to be $6.9 billion in 2018, and
in the near future, it is expected to reach $10.4 billion by 2024.[81]
Diabetic retinopathy is the leading cause of blindness in diabetic
patients and in working-age adults.[2] It results from damages of blood
vessels in the retina, resulting in leakage of blood and other fluids into
the retinal tissue followed by cloudy or blurred vision.[2,82] Diabetic
macular edema (DME) is a swelling of the macula and a direct con-
sequence of diabetic retinopathy. In order to cure or slow down the
progression of these conditions, bolus intravitreal injections of ther-
apeutic proteins and oligonucleotides such as bevacizumab, ranibi-
zumab, infliximab, aflibercept, pegaptanib are administered.[83] These
drugs are generally administered for the neutralization of cytokines and
growth factors (Table 1). In this way, photoreceptors in the retina are
Table 1
FDA approved and off-label (*) proteins/biologics for intraocular medications and dosages.
Biologics Type of
biologics
Route Clinical phase Therapy.
Indications
Mw (kDa) Half-life after administration Stand.
Dose
Ref.
Bevacizumab (Avastin®) Anti -VEGF Ivt Off-label drug
(2004)
Wet AMD*, DR*,
DM*
149 4.9 days human
4.3 days in rabbit
1.25mg/50μl [45,93]
Ranibizumab
(Lucentis®)
Anti-VEGF Ivt FDA-approved
(2006)
Wet AMD, DME,
DR*
48 2.88 days rabbit
9 days human
0.5mg/50μl [93,94]
Aflibercept (Eylea®) Anti-VEGF
(VEGF Trap-
eye)
Ivt FDA-approved
(2011)
Wet AMD,
DME,CNV,DR
115 7.1 days human
3.63 days rabbit
2mg/
50μl
[95,96]
Pegaptanib sodium
(Macugen®)
VEGF
inhibitor
Ivt FDA approved
(2004)
Wet AMD, DR*,
DME*
50 10 days human 0.3mg /90 μl [96–98]
Adalimumab (Humira®) Anti-TNFα SC FDA-approved
(July 2016)
Uveitis 148 2 weeks in human serum 40mg [99]
Infliximab Anti-TNFα Iv/Ivt Off-label for Iv Chronic
non-infectious
uveitis*
149.1 8.5 days (rabbit vitreous), 7–12
days (systemic human)
1-1.7mg/ 100 μl
(Ivt), 3-5mg/kg
(Iv)
[89,90,100,101]
Brolucizumab
(Beovu®)
anti-VEGF Ivt FDA-approved
(October 2019)
Wet AMD 26 2.4 days (cynomolgus
monkeys) in ocular
compartments
1.0 or 6.0mg/eye [91,92]
Abbreviations: Intravitreal (Ivt) injections; suprachoroidal (SC); intravenous (Iv) infusion.
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protected, and angiogenesis caused by the overexpression of vascular
endothelial growth factor (VEGF) is prevented. In 2004, the first oli-
gonucleotide-based anti-VEGF aptamer (Macugen®; Pegaptanib; Eye-
tech, Pfizer) received FDA-approval for neovascular AMD and choroidal
neovascularization (CNV) treatments.[84] The monoclonal antibody
Avastin® (Bevacizumab; Genentech) received FDA approval in 2004 for
metastatic colon cancer treatment. Importantly, bevacizumab is cur-
rently used in ophthalmology as an off-label drug for AMD, although
not yet FDA approved for these indications. Subsequently, in June
2006, a more effective monoclonal antibody (Lucentis®; ranibizumab;
Genentech) was FDA-approved for neovascular AMD and DME therapy.
Ranibizumab (48 kDa) is a Fab fragment of IgG1 and has a 17-fold
higher binding affinity for the VEGF receptor when compared to bev-
acizumab (149 kDa). In recent years, ranibizumab has shown to prevent
further vision loss in approximately 95% of patients and to improve
vision in 40% of the patients suffering from wet AMD.[85] Likewise, in
2011, Eylea® (VEGF-TRAP-Eye; aflibercept; Regeneron)[86] received
FDA approval for the treatment of CNV and wet AMD.[79] Aflibercept
(97 kDa) is a recombinant fusion protein (decoy receptor for VEGF) that
has a 200-fold higher affinity for VEGF than ranibizumab.[76] More-
over, anti-TNFα agents are also used in intraocular inflammation,
edematous neurodegenerative and neovascularization diseases as TNF’s
play an essential role in the pathogenesis of these diseases.[87] Adali-
mumab (Humira®), a monoclonal anti-TNFα for uveitis, was FDA ap-
proved in 2016 and binds specifically to TNFα (pro-inflammatory
cytokine produced by macrophages and T-cells) and therefore results in
inhibition of the inflammatory response. Infliximab (INF) is also a
monoclonal, chimeric IgG antibody that binds circulating and mem-
brane-bound TNFα, but this antibody is not yet FDA approved for
uveitis or ocular inflammation.[88–90] Beovu® (brolucizumab) devel-
oped by Novartis recently received FDA approval (October 2019) for
the treatment of wet AMD (see table 1) by intravitreal injection. The
protein is a potent anti-VEGF, which has a high affinity to all VEGF-A
isoforms. Clinical studies by randomly used intravitreal doses of bro-
lucizumab 6mg and 3mg versus aflibercept 2mg demonstrate that
Beovu was non-inferior to aflibercept in visual function after 48 weeks.
[91] Patients treated with Beovu overall showed a good improvement
in their vision and health of the eye within one year.[92] Summarizing,
anti-VEGF and anti-TNFα therapies have been very successful in the
field of ophthalmology after their FDA-approval, changing the way
vision-threatening diseases are currently treated in clinics.
2.4. Limitations of protein delivery to the posterior segment of the eye
Despite the tremendous clinical success of several novel therapeutic
proteins for the treatment of vision-threatening disorders, frequent in-
jection of these formulations cause discomfort and adversely affect
patient compliance.[102] Importantly, this class of therapeutics is hard
to formulate into long-acting delivery systems because of their struc-
tural complexity and undesired interactions with the delivery vehicle.
Fig. 2. Schematic representation of intraocular pharmacokinetics of drugs delivered by non-degradable and degradable sustained delivery systems compared to
frequent bolus intraocular injections.
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For instance, functional groups present in the hydrogel crosslinks can
potentially react with OH, COOH, SH and NH2 groups of the loaded
protein. Further, there are protein stability issues due to protein un-
folding, denaturation and aggregation, leading to loss of activity and
even unwanted immune responses.[103–107] Intravitreal injection is
the only route of administrations used today in clinics to deliver pro-
tein-based drugs to the posterior segment of the eye and eventually to
the retina. However, this approach is painful, and often monthly repeats
of injections are needed depending on the drug and disease progression.
[16,108] Furthermore when delivering proteins using other routes of
administration (e.g. topical, systemic), the poor bioavailability to in-
traocular target sites is caused by their inability to cross biological
membranes as most of the therapeutic proteins are highly hydrophilic
and have a high molecular weight.[46,109] Moreover, pharmacokinetic
and cell studies have shown that the retina, cornea and sclera have tight
junctions that limit the free diffusion of large hydrophilic molecules
through these cell layers.[76,110] So far, various attempts have been
made by formulation scientists to develop drug delivery systems that
can bypass these intraocular restrictions. However, non-targeted de-
livery of biologicals into the ocular tissues by any route of adminis-
tration may lead to drug distribution to other tissues, primarily through
the circulatory system. Therefore, drugs eliminated from the eye to
other tissues due to ocular barriers may eventually result in unwanted
side effects and toxicity.[109]
2.5. Current delivery technologies for the posterior segment of the eye
Currently, in clinics, medical doctors have the choice between
treating patients with intravitreal bolus injections (solutions and sus-
pensions) or drug-loaded implants to treat posterior eye diseases.
[111,112] Nevertheless, ophthalmologists consider current drug ther-
apeutic options insufficient regarding effective delivery and reaching
sustained therapeutic dose levels to the retina. Intravitreal pharmaco-
kinetics data show relatively rapid ocular clearance of most in-
traocularly administered drugs. As a consequence of that, drug con-
centrations in the vitreous is oscillating above and below therapeutic
levels in time with multiple bolus injections (Fig. 2).[113–115] In-
traocular implants are currently the only delivery vehicles approved by
the FDA for sustained release of intravitreally administered (small
molecular) drugs to the retina. Monolithic (polymer matrix with
homogeneous drug dispersion) and reservoir (drug particles loaded in a
core with an outer shell of a certain polymer) type of intraocular im-
plants have been produced, to treat both anterior and posterior segment
eye diseases. For the fabrication of these implants, both biodegradable
and non-biodegradable polymers have been employed. Biodegradable
implants are generally based on poly(lactic-co-glycolic acid) (PLGA),
poly(lactic acid) (PLA), or poly(glycolic acid) (PGA), while non-biode-
gradable implants are mostly made of poly(dimethylsiloxane) (PDMS),
poly(vinyl alcohol) (PVA), or poly(ethylene-co-vinyl acetate) (pEVA).
[112,116–118] These formulations are used for the controlled release of
low molecular-weight drugs, including hydrophobic steroids and hy-
drophilic drugs (e.g. ganciclovir), to yield therapeutic levels for an
extended period of time. The currently FDA approved slow-release re-
servoir implants for intravitreal administration are summarized in table
2.
Unfortunately, most of these intraocular implants are generally not
suitable as matrices for the sustained release of therapeutic proteins.
The polymeric matrix’s (e.g. EVA, PDMS) used to produce such in-
traocular implants have a high permeability for a variety of lipophilic
drugs due to their hydrophobic characteristics.[111] However, ther-
apeutic proteins are not easily released from these devices due to their
relatively large size and hydrophilicity. Furthermore, interactions of the
protein with these polymers may adversely affect protein stability.
[103] In addition, the majority of these intraocular implants require
invasive administration methods to place the devices at the target site,
and subsequent surgical procedures are needed to remove non-
biodegradable implants. This unmet clinical need triggered research
towards innovative drug delivery products such as nanocarriers (NCs),
[65,131] encapsulated cell technologies (cells embedded in a matrix
that secrete therapeutic proteins)[132,133] and stimuli-responsive de-
livery systems.[19,134,135] These novel drug delivery systems are
currently preclinically as well as clinically studied, particularly for
protein/peptide delivery to the retina (Fig. 3). Mandal et al. discuss the
major advantages and disadvantages of various preclinically/clinically
developed implants and stimuli-response delivery systems for ther-
apeutic proteins/peptides to treat ocular diseases.[76] Several products
have shown the potential to prolong the residence time of proteins in
the eye, thereby overcoming some of the limitations of ocular drug
delivery. Biodegradable products are highly favoured because these
systems do not need to be removed surgically after treatment, and their
release profiles can be engineered to reach therapeutic levels over
prolonged periods. (Fig. 2) Currently, many efforts are made by both
pharmaceutical companies and academic groups to develop intravitreal
implants for the sustained delivery of proteins.[136] Genentech re-
ported the positive phase 2 outcome of a newly developed ranibizumab
port delivery system (R-PDS),[137,138], which consists of a refillable
permanent silicone-coated implant surgically inserted through a small
incision in the sclera and pars plana. The loaded ranibizumab is re-
leased into the vitreous cavity by passive diffusion through a porous
release control element based on stainless steel or titanium.[139] This
implant was able to provide sustained VEGF inhibition during 9 months
of clinical observation in neovascular age-related macular degeneration
(nAMD) patients. Interestingly, R-PDS gave visual acuity in patients
comparable with monthly intravitreal injection of ranibizumab while
maintains the same anatomical results.[140] The product has the po-
tential of being the first device for incorporating a therapeutic protein
for posterior eye delivery.
Although there is a high demand for ground-breaking drug delivery
technologies for ocular treatments, most of the developed and in-
vestigated technologies remain at preclinical levels and very few at the
early clinical stage (Fig. 3). The slow progress of these technologies is
due to challenges in reproducibility, safety, large scale production, long
term stability. The design of an effective preclinical/clinical sustained
release system that will be able to achieve regulatory approval is im-
perative to move from “Bench to Bedside.”
3. Hydrogels for sustained intravitreal release of therapeutic
proteins
3.1. Hydrogels: general features
Hydrogels are three-dimensional networks of synthetic or natural
polymer chains crosslinked by physical and/or chemical bonds.
Compared to other delivery systems that have been developed for
posterior eye diseases such as colloidal nanocarriers (NCs) or polymeric
implants, hydrogels offer several compelling advantages. Firstly, hy-
drogels embrace numerous biomedical and pharmaceutical applications
due to their tissue-mimicking properties and desirable soft nature.
[141–144] Secondly, hydrogels are able to absorb large amounts of
water (up to 99% of their weight) while maintaining their structure due
to the presence of the crosslinks between the hydrophilic polymer
chains.[145] Therefore, hydrogels can serve as scaffolds that provide
structural integrity to tissue constructs,[146–148] and can also serve as
adhesives[149,150] or barriers between tissues.[151] Finally, as dis-
cussed in this review, hydrogels can be designed to control and/or
sustain drug and protein release to tissues due to their network struc-
ture of crosslinked polymer chains.[152,153]
Interestingly, the first publication on hydrogels for biomedical ap-
plications was in the early 1950s, when Wichterle and Lim reported on
crosslinked poly(hydroxyethyl methacrylate) (pHEMA). The aim was to
create a new biomaterial for ophthalmic applications, which led later to
the first soft contact lens.[154,155] Since this breakthrough, hydrogels
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have been of great interest to biomaterial scientists, and a great variety
of hydrogels with interesting and tailor-made properties for different
applications (drug delivery, wound dressing, tissue engineering, and
hygiene products) have been developed until today as recently sum-
marized by Cascone et al.[156] Hydrogels can be classified according to
different criteria depending on preparation methods, source, physical
properties, biodegradation and nature of crosslinking.[157] Ad-
ditionally, hydrogels can consist of homopolymers, copolymers, and/or
interpenetrating networks with different physical properties[158–160]
and can also be designed using both charged and non-charged poly-
mers. The net charge of the network might affect the release kinetics of
the loaded drug due to electrostatic interactions between the polymeric
matrix and the loaded protein.[161–163] Different types of ocular hy-
drogels with varying polymer architectures and crosslinking chemistry
have been studied preclinically to deliver proteins to the posterior
segment of the eye. (Table 3) In this review, we classify intraocular
hydrogels based on the origin of the polymers and present how the
studied hydrogels sustain the release of therapeutic proteins to treat
intraocular diseases. The main advantages and disadvantages of
polymer-based hydrogels that are currently evaluated in preclinical
studies are presented and discussed.
3.2. Hydrogels under preclinical development for sustained intravitreal
delivery of therapeutic proteins
To improve the current strategies of intraocular delivery of phar-
maceutically active proteins, suitable delivery technologies should have
the following characteristics:
1. Provide controlled and sustained release of therapeutic proteins for
at least two to three months, therefore, resulting in reduced ad-
ministration frequency.
2. Easy to administer (minimally invasive).
3. Safe and compatible with intraocular tissues with no- or very
minimal irritation.
4. Do not obstruct the vision after injection and allow patient comfort.
5. Maintain effective local drug concentration with none to very low
systemic effects compared to currently used delivery strategies in
the clinic.
6. Maintain protein stability and activity during preparation, storage
and release.
7. Undergo biodegradation; the degradation process can modulate the
release of entrapped proteins.
8. Possess physical crosslinking and/or bioorthogonal crosslinking
chemistry.
9. Allow easy manufacturing in terms of sterilization procedures,
scaling up and GMP production.
Hydrogels are considered as one of the most promising preclinically
ophthalmic biomaterials for the sustained release of bioactive proteins
to intraocular tissues. One of the most interesting features of hydrogels
is their physicochemical similarities with native tissues because they
are generally very soft and have an elastic texture with high water
content. Further, mild crosslinking conditions of polymers are presently
available for preserving the activity of entrapped biopharmaceuticals
such as proteins and peptides in the hydrogels.[152,164] The safety of
intraocular hydrogels has been evaluated in different animal models
Table 2
FDA approved intraocular implants
Implants Year of approval Description Ref
YutiqTM 2018 Non-biodegradable intravitreal implant using durasertTM delivery technology and loaded with fluocinolone acetonide (0.18mg) for
posterior uveitis, engineered to release fluocinolone acetonide over 36 months at an initial rate of 0.25μg/day
[119,120]
DexycuTM 2018 Biodegradable intravitreal implant based on the Virisome® sustained delivery technology for the treatment of postoperative eye
inflammation. This injectable implant provides sustained release of dexamethasone (103.4mg/mL in a single-dose vial) over 1-6
months.
[121]
Iluvien® 2014 Non-biodegradable intravitreal implant made of PVA matrix encased in a polyimide tube and loaded with fluocinolone acetonide
(0.19mg) for the treatment of DME over 36 months.
[122–124]
Ozurdex® 2009 Biodegradable intravitreal PLGA implant loaded with dexamethasone (0.7mg) for DME and non-infectious uveitis with a six months
release profile.
[125–128]
Retisert® 2005 intravitreal non-biodegradable (silicone/PVA) implant loaded with fluocinolone acetonide (0.59mg) to treat chronic non-infectious
posterior uveitis used up to 3 years
[127,129]
Vitrasert® 1996 non-biodegradable (PVA/EVA) implant loaded with ganciclovir (4.5mg) for the treatment of viral retinitis, developed to release the
drug over a 5 to 8 month period
[23,130]
Fig. 3. Schematic representation of currently developed drug delivery strategies to the posterior segment of the eye. Many drug delivery systems are being in-
vestigated preclinically, and some technologies have even reached clinical evaluations. However, bolus injection and intraocular implants for small molecule drugs
are still the most used therapy to treat posterior eye diseases.
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(rabbit, rat, mouse) by using different techniques. Evaluation of the
intraocular pressure after injection, fundus examination by ophthal-
moscope imaging, histological analysis and assessment of retinal func-
tion (by electroretinogram analyses) have shown that generally
speaking hydrogels are safe for intraocular use.[165–167] Furthermore,
different cell lines have been used to investigate the cytocompatibility
of hydrogels and their building blocks, and generally, no toxic effects
have been observed with the used polymers (see Table 3).
To bypass the intraocular barriers that drugs have to pass after, e.g.
topical or Iv administration (see section 2.2), drug-loaded hydrogels
can be administered by intravitreal injection in a minimally invasive
way. Importantly, hydrogels can be administered as “in-situ” forming
formulations by injection using small gauge needles into the vitreous
cavity. After intravitreal injection, the polymeric solution undergoes a
sol-to-gel phase transition, entrapping and stabilizing therapeutic pro-
teins in their hydrated network.[157,168] The gelation time, pre-
ferably, is in the order of seconds to minutes to limit the rapid and
unwanted distribution of proteins and uncrosslinked polymers due to
Fickian diffusion in the vitreous body. After gelation, the formed hy-
drogel functions as a reservoir, providing sustained release of the
loaded protein for a prolonged period of time due to the polymer net-
work that restricts protein mobility. Therefore, when properly de-
signed, this reservoir can maintain effective local concentrations of the
loaded pharmaceutically active protein in the vitreous and retina. Hy-
drogels have been successfully used for the controlled release of anti-
VEGF (ranibizumab, bevacizumab), anti-TNFα (infliximab), and ciliary
neurotrophic factor (CNTF) in the vitreous to protect vision as discussed
in details below in section 3.3 and section 3.4. [21,153,165,169,170]
Also, insulin has been released from hydrogel systems after sub-
conjunctival injection to treat diabetic retinopathy.[171] Model pro-
teins (BSA, Fab antibody fragment, IgG) have also been extensively
used to study the tunability of hydrogel systems for release character-
istics and possible unwanted or wanted interactions with hydrogel
building blocks.[172–174] Therapeutic proteins have also been loaded
together with low molecular weight drugs in hydrogels to obtain sy-
nergic effects.[152,175,176] To mention, the anti-metabolic agent 5-
fluorouracil (5FU) has been co-released with bevacizumab from N,O-
carboxymethyl chitosan (CMCS) hydrogels to modulate wound healing
and prevent scar formation after glaucoma filtration surgery[177] as
discussed in section 3.3.2. In another study, dexamethasone (Dex) was
released in combination with bevacizumab (Avastin®) from supramo-
lecular PEG-PCL micelles and α-cyclodextrin (α-CD) hydrogel to treat
inflammatory corneal neovascularization in a rat model.[178] The
hydrogel was obtained by mixing MPEG-PCL micelles with an aqueous
solution of α-CD due to the “host-guest” interaction between MPEG and
α-CD.[178,179] It was shown that 70% of the loaded Avastin® was
released within 5 days, and 70% of Dex was released in 1 day. Despite
the rapid drug release, this Dex/Avastin® hydrogel medication sup-
pressed the corneal neovascularization in the studied rat model.[178]
Proteins loaded into a hydrogel can be released through different
mechanisms, including diffusion-controlled and degradation-controlled
release.[180–182] Formulation scientists have designed hydrogels
capable of releasing proteins intraocularly from a hydrogel network in a
predictable and controlled manner by tailoring the crosslink density,
which depends on the polymer concentration, molecular weight,
polymer architecture, and degree of polymer modification with reactive
species.[152,183,184] In ophthalmology and other biomedical appli-
cations, biodegradable hydrogels are favored over non-degradable
ones. Degradable ocular hydrogels have been designed in the last dec-
ades by using both natural and synthetic polymers and combinations
thereof, selecting their building blocks as well as the applied cross-
linking strategy with particular attention.[152] The degradation rate
can be tuned by the crosslink density and the nature of degradable
linkers (by chemical and/or enzymatic hydrolysis) in the polymer
chains[183] (Fig. 4). Formulation scientists exploit these parameters to
design hydrogels with predictable and controlled protein release
profiles, as recently described in a review by Chang et al.[20]
3.3. Intravitreal hydrogels based on natural polymers as matrices for the
controlled release of therapeutic proteins
Natural polymers display multiple advantages and have been used
to develop drug delivery systems.[187,188] These advantages are re-
lated to the fact that natural polymers often display good cell adhesion
properties, and most of them are biodegradable. Specifically, poly-
saccharide-based hydrogels have often been used for the development
of ocular drug delivery systems and formulations. The most frequently
used polysaccharides are hyaluronic acid, alginate, semisynthetic chit-
osan and dextran.[189–194] Although natural polymers display many
advantages, they also have several drawbacks related to the possible
risk of infections and immunogenicity due to complexity in their pur-
ifications from natural sources.[160] However, both natural and syn-
thetic polymers allow tailoring of hydrogel properties by changing the
polymer architecture and composition (Fig. 5), initial water content and
crosslink density, as well as their degradation mechanism and kinetics
which will reflect on their release profiles.
3.3.1. Hyaluronic acid-based hydrogels for protein delivery
Hyaluronic acid (HA) is a negatively charged, naturally occurring
polysaccharide with molecular weights up to 107 Da, which is abun-
dantly present in the human vitreous body. Importantly, HA can pre-
sently be produced via biotechnological routes reducing the risks as-
sociated with the use of animal sources for this polymer.[195] HA, also
known as hyaluronan, is a glycosaminoglycan composed of repeating
disaccharide units of D-glucuronic acid and N-acetylglucosamine. HA-
based materials have been investigated for different biomedical [196]
and pharmaceutical applications.[191,197–199] Often, the carboxylic
acids or primary hydroxyl groups are chemically modified to obtain
crosslinking functionalities.[199–202] In the field of ophthalmic pro-
tein delivery, a few intraocular HA-based gels have been developed
including enzymatically crosslinked HA−tyramine conjugates, vinyl
sulfone functionalized hyaluronic acid (HA−VS) crosslinked with
thiolated dextran (Dex-SH) using a thiol-ene reaction, and HA-tetrazine
crosslinked by catalyst-free inverse-demand Diels−Alder reaction with
PEG-bisnorbornene (Table 3). Protein release from HA hydrogels can be
sustained up to a few months, depending on the protein net charge and
size, hydrogel crosslink density and degradation kinetics. As mentioned,
HA is negatively charged, and cationic proteins (pI> 7.4) can be re-
tained in the polymer network by electrostatic interactions.[163] In
addition, protein release can also be controlled by enzymatic de-
gradation of HA hydrogels by hyaluronidases,[203] which are present
in most human tissues, including the vitreous.[25]
An injectable transparent in-situ forming hydrogel based on HA-VS/
Dex-SH was formulated for intravitreal delivery of bevacizumab.[165]
The controlled release performance of this in situ forming hydrogel
formulation was evaluated in vivo in a rabbit eye model, and the for-
mulation released bevacizumab (pI ~8.3).[204] After vitreous aspira-
tion from the rabbit eye at different time points, the concentration of
released protein was measured by using an enzyme-linked im-
munosorbent assay (ELISA). Specifically, the assay determines the
amount of bevacizumab that can still bind to VEGF after being released
in the vitreous. Six months after intravitreal injection of the hydrogel
formulation (40 μl) into a rabbit eye, it was shown that the gel main-
tained intravitreal protein concentration above the therapeutic level
(> 50 ng/ml).[165] Egbu et al. reported the sustained release of in-
fliximab (INF; MW:149.100Da pI:8.25) from two gel systems based on
crosslinked HA for the treatment of intraocular inflammation. Tyr-
amine-substituted HA (HA-Tyr, 4.8 kDa) was enzymatically crosslinked
in the presence of INF to form a drug-loaded gel (HA-Tyr, INF). A
second gel was prepared by the polymerization and crosslinking of
NIPAM with poly(ethylene glycol) diacrylate (PEGDA) in the presence
of unmodified HA (50 kDa) and INF to form a thermosensitive PEGDA-
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pNIPAAM/HA semi-interpenetrating polymer network. In vitro release
of INF from these hydrogels was studied by using a two-compartment in
vitro outflow model of the human eye, called the PK-Eye. This model
was previously developed by Awwad et al. to estimate the clearance of
ocular drugs by the anterior aqueous outflow pathway. [205] The
model is made of an anterior and posterior cavity, which are separated
by a cellulose membrane. This model previously showed clearance
values for the studied drugs (ranibizumab, bevacizumab, triamcinolone
acetonide) that were comparable to that observed in humans.[205]
Egbu et al. showed that the two hydrogel formulations had a controlled
release of INF, with the slowest release rate being ~25% of the loaded
protein in 9 days.[169] However, important issues among which the in
vitro hydrogel cytotoxicity, in vivo biocompatibility, possible inter-
ference of protein functional groups in the crosslinking reaction and
protein activity after release from the hydrogels were not addressed in
this study. Tetrazine-modified HA and norbornene-modified poly
(ethene glycol) were used to obtain an HA-Tz/PEG-bisnorbornene hy-
drogel for in-situ encapsulation of a Fab fragment (Fab1) as a model
protein.[172] In this hydrogel system, a catalyst-free inverse-demand
Diels−Alder reaction between tetrazine and norbornene groups was
used to exploit the bio-orthogonal nature and protein friendly condi-
tions of this crosslinking method (Fig. 6). At room temperature, the
gelation of the soluble hydrogel precursors occurred within 3 min.[172]
Protein release kinetics showed that the hydrogels formed from 20 and
50mg/mL HA showed a sustained release of Fab1 with a daily release
rate> 1μg for 7 and 27 days, respectively (Fig. 6A-B). Importantly,
more than 95% of the loaded Fab1 was released from the hydrogels
suggesting that the protein was physically entrapped and had not un-
dergone covalent bond formation with the hydrogel matrix.[172] The
integrity of the released protein was analyzed by size-exclusion
Fig. 4. Schematic representation of the correlation between the release rate of protein therapeutics and the mesh size (ξ) of the hydrogel network, as illustrated by the
three hydrogels. The curves A, B and C show different release profiles depending on the drug molecular weight and changes in hydrogel pore size over time due to
swelling and degradation. Low molecular weight drugs are generally released from hydrogels by Fickian diffusion because their size is much smaller than the
hydrogel mesh-size. On the other hand, the release rate of larger molecules such as pharmaceutical proteins is determined by degradation and swelling rate of the
hydrogel when the protein is entrapped in the hydrogels matrix, meaning that their hydrodynamic size is larger than the hydrogel mesh size.[185,186] The blue A
curve represents a fast first-order release of a loaded small drug, whereas the green B curve indicates sustained first-order release of a loaded therapeutic with a
relatively low molecular weight (e.g. a Fab fragment). The release follows first-order kinetics since the released amount is proportional to the square root of time,
meaning that the size of the loaded therapeutics is smaller than the pore size of the hydrogel and that the hydrogel is dimensionally stable during the release time.
The red C curve represents delayed-release kinetics of a loaded therapeutic (e.g. a full IgG type antibody). Here the protein is initially entrapped in the pores of the
hydrogel and only releases when the crosslink density decreases (and thus pore size increases) over time due to degradation.[174,183]
Fig. 5. Schematic representation of hydrogel design for protein delivery to the back of the eye using natural synthetic polymers.
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chromatography (SEC), ion-exchange chromatography (IEC) and by
liquid chromatography-mass spectrometry (LC-MS). The proteins
maintained their structure during their residence time within the hy-
drogel network at 37oC and did not carry fragments of hydrogel pre-
cursors. Although the authors had not investigated this system for in-
traocular protein delivery, the in vitro release data are encouraging and
suggest that intraocular release of ranibizumab may be achievable as
well with this system. Furthermore, additional in vitro, in vivo studies,
degradability studies and protein bioactivity after been released from
the gel are necessary to ascertain whether this delivery system is indeed
safe and suitable for intraocular use.
3.3.2. Intravitreal hydrogels based on chitosan
Both natural (alginate, dextran, hyaluronic acid and gelatin) and
semi-synthetic polymers (chitosan) have been successfully used to
prepare different drug delivery systems for ophthalmological applica-
tions.[206]
These polymers are primarily used in the preparation of nano- or
micro technology-based drug carriers but also for the development of in
situ gels for the delivery of low molecular weight drugs such as corti-
costeroids, antibiotics, antimetabolites and siRNA mainly for topical
therapy.[207–215] In contrast, fewer studies are showing the potential
use of these natural polymer based materials for ocular delivery of
pharmaceutical proteins.[216–218]
Chitosan is a cationic polysaccharide that is prepared from the
natural polymer chitin after partial or complete deacetylation. In oph-
thalmic applications, chitosan-based nanocarriers and in situ forming
gels have been extensively investigated for the delivery of low mole-
cular weight drugs mostly to prolong the release of topically adminis-
tered drugs.[219–221] There are some promising examples of chitosan-
based drug delivery strategies to deliver pharmaceutical proteins, using
nano- or micro particles and hydrogels.[222,223] The in vitro sustained
release of bevacizumab and ranibizumab from chitosan-PLGA nano- or
micro- particles have been studied by Pandit et al.[224] and Elsaid et al.
[225] for posterior eye therapy. The studied chitosan PLGA nano- or
micro- particles release 15% of loaded bevacizumab within 72h of the
study, while ranibizumab showed a biphasic release profile with an
initial 20% burst release followed by a second dose after ~135 days.
Although chitosan is not soluble in water at a pH of 7.4, chitosan can be
dissolved in acidic solution, and because of the charged amino groups,
it is able to interact spontaneously with anionic polymers to form a
hydrogel network.[226–228] Chitosan hydrogel systems are being
studied for the delivery of small drugs such as ciprofloxacin [229],
chloramphenicol [230], and latanoprost [231]) for ocular applications.
[232–234]
Xu et al. studied the sustained release of bevacizumab from an al-
ginate-chitosan hydrogel.[223] Specifically, the hydrogel network was
formed by glycol chitosan crosslinked by oxidized alginate. The hy-
drogel completely released the protein within three days. This release
rate is too fast for long term ocular treatments; therefore, more ex-
tended release profiles should be investigated. The in vitro and in vivo
toxicity in relevant models were not reported in this study.
Carboxymethyl chitosan is a water-soluble polysaccharide with
good biocompatibility used to prepare hydrogels for pharmaceutical
applications. Li-Qun Yang et al. described O-carboxymethyl chitosan
(CMCS) in-situ forming hydrogels for intraocular delivery of 5-fluor-
ouracil (5-FU) or bevacizumab using genipin as the water-soluble
crosslinker.[177] After subconjunctival injection, the effect of this drug-
loaded CMCS hydrogel in modulating wound healing and reducing
postoperative IOP values following glaucoma filtration surgery on
rabbits was evaluated. As expected, based on the molecular weight of
the drugs, it was shown that that bevacizumab was released slower
(20% after 53h, by anomalous transport) from the hydrogel than 5FU
(8h, by Fickian diffusion). In vivo evaluation showed that the CMCS
hydrogels were compatible with the cornea and gradually biodegraded
in the rabbit’s eye. However, the mechanism that governs the de-
gradation was not studied. Drug-loaded CMCS hydrogels effectively
delayed subconjunctival scar formation after glaucoma filtration sur-
gery and controlled postoperative IOP.[177] However, it is essential to
consider that genipin can readily react with primary amines present in
lysine residues of proteins that could potentially alter the structure of
the protein and its function.[235] This hydrogel system has shown to
Fig. 6. Schematic representation of the reaction between tetrazine-modified hyaluronic acid and poly(ethylene glycol) bis-norbornene at physiological conditions
reported by Famili et al.[172] to form an in situ hydrogel network. A) Release of a model Fab1 protein from an in-situ formed gel based on HA-TZ, PEG-bisnorbornene
hydrogel in PBS at 37oC. Both high (50mg/ml) and low (20mg/ml) starting polymer concentrations resulted in hydrogels, which showed a quantitative release of
Fab1, suggesting that the protein has not undergone unwanted reaction with the functional groups present in the hydrogel building blocks. B) Hydrogels formed from
20 and 50mg/mL HA showed a sustained release of the loaded Fab1 protein>1 μg/day for 7 and 27 days, respectively. Data points represent mean± standard
deviation of n = 3 replicates. Adapted and reprinted with permission from [172] Copyright © 2017 American Chemical Society.
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increase the therapeutic efficacy of glaucoma filtration surgery, and in
future studies, it would be interesting to investigate their potential use
as long term protein release depot for ocular applications.
3.4. Intravitreal hydrogels based on synthetic polymers as matrices for the
controlled release of therapeutic proteins
Hydrogels based on synthetic polymers have been used as release
systems of bioactives into the eye. Poly(ethylene glycol) (PEG), poly(2-
hydroxyethyl methacrylate) (pHEMA), poly(vinyl alcohol) (PVA),
polyacrylamide (PAM), poly(D,L-lactide-co-glycolide) (PLGA), poly(ε-
caprolactone) (PCL) are the most commonly used synthetic polymers to
prepare ocular drug delivery systems.[206,236,237] PEG is a frequently
used synthetic polymer for biomedical and pharmaceutical applica-
tions, also in ophthalmology. It is a water-soluble polymer that can be
eliminated from the circulation by the kidneys up to a molecular weight
of 50 kDa.[238] Since 1990, several PEG-based pharmaceutical pro-
ducts have been approved by the FDA for clinical use.[236,239,240]
Jing Yu et al. used an in-situ covalently crosslinked PEG hydrogel for the
intraocular delivery of Avastin® (bevacizumab).[241] The PEG hydro-
gels were formed via a thiol-maleimide reaction between 4-arm PEG-
Mal and 4-arm PEG-SH at physiological conditions. Variation of
polymer concentrations yielded PEG hydrogels with differences in ge-
lation time, the extent of swelling, pore size and mechanical properties.
These PEG hydrogels and their leachables were non-toxic to L-929 cells
after seven days of cell culture. Importantly, L-929 cells on the surface
of this PEG hydrogel showed a different morphology and did not pro-
liferate because of poor cell adhesion. Since the system is aimed to
function as a long-term intravitreal reservoir, the fact that cells do not
adhere to the hydrogel surface might be beneficial to prevent undesired
cell adhesion and proliferation on the hydrogel depot. The PEG hy-
drogel formulation showed in vitro (PBS buffer of pH 7.4 and at 37 oC)
release of 25% encapsulated bevacizumab within 1 day and subse-
quently released 70% of the loaded protein for the subsequent 14 days.
Further, sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) showed that no fragments with molecular weights smaller
than that of the native protein were detected. However, the authors did
not show whether the activity of the released protein was retained.
[241] Besides the examples given above, many other in-situ forming
PEG hydrogels have been investigated to deliver both pharmaceutical
proteins and low-molecular-weight drugs with promising results for
ophthalmic application. [173,241–244] Imperiale et al. summarized
the use of synthetic and natural polymers for ophthalmic drug delivery.
[206] Synthetic and natural polymers can be engineered to stimuli-re-
sponsive hydrogels, meaning that they jellify or release drugs from their
network in response to external stimuli (for example, changes in tem-
perature, oxidation, light intensity, pH, ionic strength). These hydrogels
are very attractive for ophthalmic applications as they can be formed in
situ in the ocular tissues. However, the majority of currently developed
stimuli-sensitive hydrogels are focused on the topical delivery of small
molecular drugs. [209,245–248] While, in protein delivery, light-acti-
vated gels (section 3.4.1) and temperature-sensitive hydrogels (de-
scribed in section 3.4.2), are the most commonly developed systems for
intraocular medications.
3.4.1. Photosensitive synthetic hydrogels:
Light-activated in situ forming gels are an attractive concept for
intraocular delivery mainly because light can travel to the posterior
segment from the anterior segment, causing the formation of an in situ
hydrogel network. Thus, after injection or deposition of hydrogel pre-
cursors in the eye, light can be used together with a photoinitiator to
photocrosslink the gel in situ. Furthermore, the release of therapeutic
proteins from the hydrogel depot can also be photo-modulated, as de-
scribed in section 3.5. Tyagi et al. reported about a light-activated, in
situ forming gel based on polycaprolactone dimethacrylate and hy-
droxyethyl methacrylate.[249] The gel network was formed in the
presence of a photoinitiator 2-dimethoxy-2-phenylacetophenone
(DMPA) and 365 nm UV light. After 10 minutes of crosslinking, the gel
network was able to sustain the delivery of bevacizumab up to 4 months
in vitro after an initial 20% burst release. In vivo studies showed sus-
tained release in the suprachoroidal space for at least 60 days in a rat
model. Williams et al. investigated the extended-release of bev-
acizumab by embedding protein containing microparticles into hy-
drogel matrices (based on photocurable PEG).[250] The in vitro release
profile from this system showed a zero-order release of active bev-
acizumab over 90 days.
Although photosensitive hydrogels may represent an interesting
delivery strategy for ocular application, several drawbacks could limit
the clinical translation. The use of photoinitiators that form free radi-
cals upon exposure to light could potentially harm ocular tissues or the
encapsulated protein cargo. Long crosslinking times may also be an
issue as the use of specific laser light and wavelengths may not be well
tolerated by the eye.
3.4.2. Temperature-sensitive synthetic hydrogels
Due to the fast in-situ gelation properties, temperature-sensitive
hydrogels have been frequently investigated as systems that slowly
release therapeutic proteins to the back of the eye. After the adminis-
tration of the formulation, the change from room to body temperature
triggers its gelation. These systems are characterized by a phase tran-
sition at a certain temperature in aqueous solutions, which is known as
“lower critical solution temperature (LCST) behavior.”[251] Thermo-
responsive polymers most commonly used in the pharmaceutical field
for the formulation of injectable hydrogels are characterized by an
LCST between room and body temperature. Formulations based on this
type of polymers can be used as injectable release systems since they are
liquid at room temperature and jellify rapidly at body temperature after
administration. Therapeutics can be easily loaded in these gels by dis-
solving/dispersing them in the hydrogel precursor solution. After
crosslinking, the encapsulated drugs will be released in a controlled
manner with kinetics depending amongst others on the size of the
therapeutic agent, hydrogel pore size and swelling/degradation. Tem-
perature-sensitive polymers can be either synthetic or natural origin.
However, in this review, we focus on synthetic thermosensitive poly-
mers since they have been predominantly used to deliver and release
proteins to the retina. The most frequently investigated thermosensitive
polymers are poly-(N-isopropylacrylamide) (PNIPAM), poloxamers
(Pluronics®), poloxamines (Tetronics®), poly(methacrylamide hydro-
xylpropyl lactate) (pHPMAm-lac), poly(2-ethyl-2-oxazoline)-b-poly(ε-
caprolactone)-b-poly(2-ethyl-2-oxazoline) (PEOz-PCL-PEOz), and poly
(DL-lactic acid-co-glycolic acid) (PLGA)–polyethylene glycol
(PEG)–PLGA (PLGA-PEG-PLGA). These polymers can be derivatized
with functional groups that allow chemical crosslinking for further
stabilization of the hydrogel network. Hydrogels obtained by covalent
crosslinking of thermosensitive polymers swell below the LCST but
collapse (shrink) above the LCST.[251] Xie et al. reported the use of a
thermosensitive PLGA-PEG-PLGA hydrogel for sustained release of
Avastin® to treat posterior segment diseases.[252] The sol-gel transition
of the system occurred at 26oC, as demonstrated by rheological studies.
However, the Avastin® loaded PLGA-PEG-PLGA hydrogel showed lower
gelation temperatures of 22-24oC depending on the concentration of the
protein. The authors suggest that hydrophobic regions of the protein
might interact with hydrophobic polymer segments of PLGA-PEG-
PLGA, resulting in a lower gel formation temperature. The authors also
mentioned that a similar result was reported by Park et al.[253] It
should be remarked that these hydrophobic interactions might cause
undesired protein unfolding resulting in loss of its biological activity.
Furthermore, although a fast thermal transition is observed at these
temperatures (22-26oC), the LCST temperature close to room tem-
perature might cause unwanted gelation prior to the intravitreal in-
jection. The authors claimed that the system slowly releases the protein
up to 14 days in vitro. However, reported data showed a 10-13% release
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within 8 hours, followed by marginal release (< 2.5% of the loaded
amount of protein) for two weeks.[252] Nevertheless, in vivo pharma-
cokinetic studies (formulations were injected in rat eyes) showed that
the PLGA-PEG-PLGA hydrogel could extend the presence of Avastin® in
the vitreous humor and retina for 4 weeks (35±14 ng/mL) compared
with bolus injection (no Avastin® was detected in the vitreous humor
after 4 weeks).[252]
PNIPAm gained substantial attention for biomedical and pharma-
ceutical applications after being described by Heskins and Guillet as a
temperature-dependent phase transition polymer in aqueous solution.
[254–256] This phase transition (LCST) occurs at 32oC and is suitable
for the design of in-situ gelling systems.[257,258] PNIPAM has iso-
propyl (CH(CH3)2) and amide (CONH) moieties in its structure. Below
the LCST, the polymer is soluble in water because of hydration of the
amide bonds, whereas above this temperature, the hydrophobic char-
acteristics of the isopropyl groups dominate the properties in water,
resulting in polymer precipitation.[256] The incorporation of hydro-
philic monomers in the polymer chains results in an increased LSCT,
while more hydrophobic units decrease the LCST. [259] Because of its
attractive characteristics, PNIPAm based hydrogels have been studied
as drug delivery systems for various applications, including ocular
therapy.[173,260–263] However, PNIPAM based hydrogels can be very
fragile and unstable, resulting in the relatively fast release of the loaded
drugs.[260,264] Furthermore, at high concentrations, both physically
and chemically crosslinked PNIPAM-based hydrogels often show a
common phenomenon known as syneresis due to the shrinking of gel
size with the expulsion of water from the network.[265] This dehy-
dration of the network will mediate the rapid expulsion and release of
proteins and/or cause undesired gel-protein interactions.[260] There
are different ways to enhance the mechanical stability of PNIPAM hy-
drogels, as reviewed by Haq et al.[264] For instance, an inter-
penetrating polymer network can be formed by the incorporation of
another polymer in the hydrogel matrix to obtain a multicomponent
polymeric system.[266–268] PNIPAM can be co-polymerized with dif-
ferent monomers, e.g. acrylic acid (AA),[269] N, N-dimethylacrylamide
(DMA)[270] to prevent syneresis.[271,272] Alternatively, PNIPAM
copolymerized with functional monomers can be covalently crosslinked
with other complementary polymers by, e.g. azide/alkene click chem-
istry, Michael addition, photopolymerization and thiol-ene reactions to
form stable hydrogels. [273–275] It should be mentioned that pNIPAM
and its copolymers with hydrophilic and/or hydrophobic monomers are
generally not biodegradable, which represents a major limitation for its
use as a drug delivery system for the eye. Nevertheless, several PNIPAM
copolymers have been engineered to obtain networks that are degrad-
able under physiological conditions. For example, PNIPAM copolymers
with hydrolyzable side groups can, in time, result in the formation of
soluble polymer chains, which can be eliminated by the kidneys when
the molecular weight is sufficiently low.[7,276] Neradovic et al. de-
veloped an AB block copolymer of PEG (A block) and a random copo-
lymer of NIPAM and N-(2-hydroxypropyl) methacrylamide lactate
(HPMAm-lactate) (B block).[277] Interestingly, these block copolymers
formed micelles at 37 oC which is above the LCST of the B block, but
after hydrolysis of the lactate side groups, the cloud point (CP) in-
creased above 37°C resulting in the dissolution of the polymers. Since
then, other copolymers of NIPAM with hydrolytically labile monomers
have been developed.[278–282] Vernon et al. reported on the hydro-
lysis-dependent degradation of NIPAM copolymerized with dimethyl-γ-
butyrolactone acrylate (DBA). As shown in Fig. 7, after hydrolysis of
DBA, the overall polymer becomes more hydrophilic due to the for-
mation of hydroxyl and carboxyl groups that will then promote polymer
dissolution.[280,281] The suitability of NIPAM and DBA copolymers
for injectable hydrogels for biomedical applications was demonstrated
for example by Vo et al. and Boere et al.[282,283]
Imai et al. reported on a synthetic subconjunctival implanted hy-
drogel for sustained release of insulin to rescue retinal neurons from
apoptosis in diabetic rats.[171] The hydrogel was synthesized by UV
photopolymerization of N-isopropylacrylamide and a dextran mac-
romer containing oligolactate-(2-hydroxyethyl methacrylate) units.
FITC-insulin was dissolved in N, N-dimethylformamide (DMF) together
with hydrogel precursors and upon UV polymerization in a Teflon
mold, FITC-insulin–loaded hydrogels were obtained. This protein was
released from this gel in vitro for least five months by a combination of
degradation and diffusion, depending on the hydrogel composition.
[171] Interestingly, FITC-insulin released from the hydrogel after sub-
conjunctival injection could be detected on the target site (euthanized
retina model) by confocal imaging. In vivo, biosafety studies showed
normal retinal histology after two months post blank hydrogel im-
plantation in Sprague-Dawley rats. The developed poly(NIPAm-Dex-
lactate HEMA) hydrogels showed the capacity to release biologically
active insulin for 1 month to the retina via subconjunctival implanta-
tion with the potential to minimize DR without the risk of hypogly-
cemia. Although the authors showed that there was no toxicity in the
animal model, possible residual of DMF present after preparation and
purification of the hydrogel may pose a risk for toxicity in the eye.[171]
Derwent et al. developed thermoresponsive hydrogels as drug delivery
systems for ocular applications.[173] Poly(ethylene glycol) diacrylate
(PEG-DA) was polymerized with NIPAM to obtain a non-degradable
hydrogel, which was used to encapsulate bovine serum albumin (BSA)
and immunoglobulin G (IgG) as model proteins. The crosslinked PNI-
PAm−PEG-DA hydrogel showed a phase transition at 32oC and was
injectable using a 27-30 gauge needle below this temperature. This
injection was possible because, at room temperature, the formulation is
liquid but rapidly gelated within 1 minute at 37oC. The release kinetics
of the loaded proteins could be tuned by varying the ratio of PEG-DA/
NIPAM and, therefore, the crosslink density. The different hydrogels
showed a rapid release within 48 hours of the loaded proteins, which
might be due to the initial volume collapse of the hydrogel in response
to temperature. Thereafter, the loaded proteins were released for three
weeks. In vivo tests confirmed hydrogel formation in the vitreous of a
rat model after intravitreal injections of a FITC-labeled hydrogel for-
mulation. A fluorescein angiography image of the FITC-hydrogel
showed the localized formation of the gel in vitreous, and no adverse
effects on the retina were observed in histological studies.[173] Fur-
thermore, a test on retinal function after the injection of PEG-DA
crosslinked PNIPAm hydrogel showed a limited transient effect on
retinal function without any long-term adverse effects.[166] However,
the clinical translation of this formulation is unlikely because the gel
system does not degrade under physiological conditions. Wang et al.
developed a thermosensitive and biodegradable hydrogel based on a
triblock copolymer of poly(2-ethyl-2-oxazoline)-b-poly(caprolactone)-
b-poly(2-ethyl-2-oxazoline)(PEOz-PCL-PEOz) which was used as an
intraocular controlled release system for bevacizumab (Fig. 8).[284]
The aqueous solution of the polymer showed a reversible sol (room
temperature) −gel (physiological temperature) phase transition to
yield a hydrogel. The protein was loaded in the hydrogel by the dis-
solution of bevacizumab with the PEOz-PCL-PEOz triblock copolymer
at low temperature, and subsequently, the temperature of the obtained
solution was increased to 37oC. The formed hydrogel was incubated in
balanced salt solution as the standard saline for intraocular use (BSS) at
37 oC, and the released protein was detected by enzyme immunoassay
(ELISA). During the first 11 days, a diffusion-controlled release was
observed, while from day 12 to 20, the release was controlled by a
combination of diffusion and erosion. Overall, 80% of the loaded bev-
acizumab was released from the hydrogel network in 20 days (Fig. 8A),
and the released protein was able to bind to VEGF, demonstrating that
the biological activity of the protein was preserved. However, longer-
term release profiles should be aimed as currently soluble bevacizumab
is typically administered once a month. The hydrogel hydrolytic de-
gradation was conducted at 37°C in BSS and analyzed by scanning
electron microscope. Initially, the hydrogel surface morphology was
smooth and became more and more porous over time due to hydrogel
erosion. After ten days of degradation, pores of 10−20 μm in size were
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seen, and channels were observed through which the protein could
have been released. In vivo studies demonstrated that the hydrogel was
formed in a localized position in the vitreous after intravitreal injection.
Histomorphology and electrophysiology were studied on rabbit neu-
roretina, and normal functions were preserved two months after in-
jection and thus showing the safety of this system in the rabbit eye.
Gregoritza et al. investigated the controlled release of bevacizumab
from a degradable thermoresponsive hydrogel crosslinked by Diels-
alder chemistry (see Fig. 9).[285] The hydrogel was prepared by re-
acting maleimide modified four, and eight-armed poloxamines with
furyl modified four and eight-armed poloxamines. This thermal gel
showed a rapid sol-gel transition at 37oC due to its thermosensitivity,
which was stabilized by the Diels-Alder click reaction between the
maleimide and furyl groups. The obtained gels released>90% of the
loaded protein over a period of 7, 21 and 115 days, depending on the
used ratios between four- and eight-armed polymers at a fixed polymer
total concentration. Furthermore, binding studies of the released anti-
body at 7 and 30 days demonstrated that the structural integrity of the
released protein was almost fully preserved. The hydrogel might be
beneficial for the treatment of ocular neovascularization.
Rauck et al. investigated the in vivo release of bevacizumab from
poly(ethylene glycol)-poly-(serinol hexamethylene urethane) thermal
hydrogels (ESHU) after intravitreal injection in a rabbit eye.[286]
Rheological studies on ESHU solution in phosphate-buffered saline
showed a phase transition at 32°C with a maximum elastic modulus at
37°C as previously described by Park et al.[287] Rauck and co-workers
analyzed samples obtained from the anterior chamber paracentesis to
quantify the concentrations of released protein using ELISA.[286]
Compared to bolus bevacizumab injections, ESHU hydrogels were able
to sustain therapeutically active bevacizumab intravitreal concentra-
tions for nine weeks, which is ~4-5 times longer than observed after the
injection of the free protein (~2 weeks).[286]
3.5. Hybrid-delivery hydrogel technologies
Besides the dispersion/dissolution of a proteinaceous drug in a hy-
drogel matrix, sustained release can also be obtained by incorporating
drug-loaded polymeric nanoparticles, microparticles, micelles and
liposomes in a hydrogel network, which is named hybrid-delivery
technology.[134,217,288] As previously discussed in section 2.2.3,
drug delivery particles with size< 500nm generally diffuse rapidly in
the vitreous and are rapidly cleared from the posterior segment, espe-
cially if neutrally or negatively charged. Therefore once loaded in hy-
drogels, drug-loaded particles are immobile and thus retained at the site
of administration. Rong et al. recently evaluated the use of insulin-
loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel (ICNPH) for a
neuroprotective effect in a diabetic retinopathy rat model.[167] The
primary objective of the study was to provide evidence for its potential
clinical application for DR. After subconjunctival injection of ICNPH in
diabetic rats, retinal histological and functional changes were evaluated
at different time points. The authors showed that the system was able to
protect retinal function, reduced cell apoptosis and decreased VEGF
expressions compared to controls.[167] Another intraocular hybrid
nanoparticles/hydrogel delivery technology was studied by Basuki et al.
[170], who described the use of polymer-coated gold nanoparticles
(AuNPs) loaded in an agarose hydrogel as a depot for intraocular de-
livery of both model proteins (BSA, IgG) and therapeutic proteins
(bevacizumab, ranibizumab, conbercept). The system was engineered
to release the proteins to the retina by a visible light-trigger with an
“on-off” release mechanism for non-invasive repetitive dosing. The
exposure of visible light (400-500 nm, 508 mW/cm2, 10 min) caused a
localized temperature increase of the hydrogel depot (up to 50 oC) due
to the conversion of photons to thermal energy by gold nanostructures.
As a result, the agarose matrix underwent a reversible reduction of the
storage modulus (G’) that resulted in the triggered release of the pre-
loaded proteins. This reduction of G’ is associated with lower crosslink
density, increased swelling and thus larger mesh size of the network.
The authors showed the in vitro “on-off” release of the loaded proteins
from a 2% agarose 0.01% polymer-coated gold nanoparticles (AuNPs)
agarose hydrogel (AuNPs hydrogel), and the rates were generally
comparable.[170] The system showed photo-thermal modulation after
implantation of the depot loaded with FITC-BSA in the anterior
chamber of an isolated bovine eye since high intensity of the FITC-BSA
was measured in the aqueous humour after light exposure compared to
suitable controls. It would be interesting to study the photo-thermal
modulation of this system after intravitreal implantation, as released
Fig. 7. Synthesis and hydrolysis of poly(NIPAAM-co-dimethyl-γ-butyrolactone). Adapted and reprinted with permission from [280] Copyright © 2007, American
Chemical Society.
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protein from the hydrogel matrix can easily diffuse to the retina. The
system may have good potential as an on-demand release of ther-
apeutics for the treatment of various chronic diseases. Further, the
authors did neither discuss nor show data regarding the biodegrad-
ability and elimination of the delivery system after the complete release
of the loaded proteins. No toxicity was shown to L929 (mouse fibro-
blasts) after 2 minutes of exposure to blue light (400-500 nm) with
increasing light intensity at a fixed distance. However, blue light can
cause loss of mitochondrial respiratory activity and therefore result in a
decrease of retinal cells viability, as shown by Godley et al.[289]
Therefore, parameters such as blue light exposure time, light intensity
and wavelength should be investigated carefully and optimized to
prevent undesired toxicity to retinal tissues.
4. Current challenges for ocular protein delivery by hydrogels
Despite the many advantages of hydrogel-based protein delivery
systems, several important issues have to be addressed to develop an
effective intraocular drug delivery system suitable for clinical transla-
tion and application.
4.1. Protein stability
The physical and chemical stability of the encapsulated and released
proteins is crucial at the different stages of drug delivery system de-
velopment. Ideally, the protein should retain its complex secondary and
tertiary structure and biological activity during loading, storage and
release, because the loss of structural integrity can result in unwanted
immunological responses.[104–106,290] Hydrogels have proven to
stabilize proteins by limiting their mobility in the network structure.
[291–293] However, the development of in-situ forming hydrogel for-
mulations with crosslinking mechanisms that do not interfere with
different functional groups in proteins (e.g. NH2 and SH groups) is a
major challenge. Some of the developed crosslinking methods make use
of thiol-ene, thiol-maleimide, and Diels-Alder reactions, which can re-
sult in highly unwanted chemical immobilization of the protein mole-
cules onto the hydrogel network.[294–296] The grafted proteins will
only be released upon degradation of the network. Moreover, the re-
leased proteins may still carry fragments of the network, which in turn
may compromise protein activity and might even induce im-
munogenicity.[106] Double-bonds, present in compounds carrying
vinyl sulfone (VS), (metha)crylate, and maleimide groups are reactive
towards thiols and amines present in proteins. Yu et al. reported that the
formation of covalent bonds between bevacizumab and HA-VS of hy-
drogel networks results in an incomplete release of the encapsulated
protein (less than 20% of the loaded protein was released).[294] The
authors suggest the use of De Gennes’s blob theoretical model for
polymers at the semi-dilute state[297] as guidance to reduce the
Fig. 8. Schematic representation of the synthesis method of amphiphilic PEOz-PCL-PEOz triblock copolymer. A) In vitro cumulative release of bevacizumab from 20
wt % ECE hydrogel. B) Crosslinked PEOz-PCL-PEOz hydrogel particles at 37°C in a viscous solution (B). Adapted and reprinted with permission from [284] Copyright
© 2012, American Chemical Society.
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chemical grafting of proteins to the vinylsulfone-thiol (VS-SH) hydrogel
network.[294] According to this blob model, polymer chains in semi-
dilute solutions can interact with each other at the entanglement points.
The authors compared such polymers to the in-situ crosslinked hydrogel
state from the blob perspective in which the VS-SH hydrogel is formed
by chemically crosslinking at the entanglement points. They discussed
that the covalent grafting of proteins in the hydrogel network via re-
action of, e.g. SH in the protein and VS groups of the polymer is due to
the mismatch between reactive groups and the entanglement points,
leaving many unreacted VS and SH groups. Therefore, protein grafting
to the polymer chains was reduced by using a higher degree of mod-
ification (DM) and a higher concentration of SH polymers compared to
VS polymers. This strategy was used to decrease the number of un-
reacted VS groups to achieve extended-release profiles of approxi-
mately 60% unmodified proteins for 3 months.[294] As previously
discussed Gregoritza et al.[285] reported that bevacizumab released
from a Diels-Alder (furan-maleimide) in-situ forming hydrogel had the
same affinity for the VEGF receptor as native bevacizumab by using
ELISA assay. However, the authors did not analyze whether the released
protein contained fragments of the degraded polymer network, which
might, as mention before, induce unwanted immune responses.
Nevertheless, the potential and unwanted protein reactions with groups
present in hydrogel precursors remain one of the major hurdles faced
today. Famili et al.[172] report the development of bio-orthogonal
crosslinking chemistries that enable in-situ protein encapsulation
without competing reactions with protein functional groups to provide
sustained and complete release, as discussed in detail in section 3.3.1.
The pH of the formulation is another critical parameter to consider as
both very low and high pH values can be detrimental for protein sta-
bility and activity due to irreversible conformational changes. Further,
the pH, concentration and type of buffering salt can influence many
degradation pathways such as deamidation, disulfide bond formation/
exchange, isomerization, and fragmentation.[298–300] The optimum
pH value varies largely depending on the type of protein. Generally, a
weak acidic buffer is optimal for the storage of most antibodies.[298]
For example, some of the presently used antibodies such as adali-
mumab, ranibizumab, and bevacizumab are formulated in slightly
acidic buffers (pH 5.2, 5.5 and 6.2, respectively, below their isoelectric
points (~8.3- 8.8)[50,301,302] for ocular treatments.[285]
4.2. Hydrogel turbidity and viscosity
Hydrogels for intraocular delivery are often designed to be ther-
mosensitive hydrogels. However, some of these hydrogels (based on,
e.g. PNIPAM, PLGA-PEG-PLGA, PEOz-PCL-PEOz), become turbid at
physiological temperature resulting in non-transparent hydrogels.
(Fig. 8B) This phenomenon raises the question of whether hydrogels
injected in the vitreous body need to be transparent. There are no re-
strictions on whether a formulation or device injected into the eye has
to be transparent or not.[164] Nevertheless, from the patient's view-
point, transparency would be beneficial, and accordingly, some for-
mulation scientists conclude that transparency is a significant asset,
[165,173,217] Nevertheless, the human eye vitreous volume (~4 ml) is
relatively large in comparison with the typically injected formulation
Fig. 9. Schematic representation of poloxamines with multiple maleimide or furyl groups used for hydrogel formation by Diels-Alder reaction. In vitro release of
bevacizumab from 0%/30% (A), 5%/25% (B), and 10%/20% (C) 8armPoloxamine to 4armPoloxamine ratios Diels-Alder hydrogels in phosphate buffer, pH 7.4 at
37oC. Adapted and reprinted with permission from [285] Copyright © 2017 American Chemical Society.
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volume (50 μl). Therefore, hydrogel turbidity does not seem to re-
present a major obstacle when the hydrogel is injected and localized
outside of the visual path (e.g. behind the iris). Derwent et al. reported
the localized presence of a thermosensitive FITC-labeled hydrogel in an
adult rat model after intravitreal injection. Laser ophthalmoscope
images demonstrated that the hydrogel formed locally, and no fluor-
escence from any other location in the vitreous was observed, and thus
the injected hydrogel might not interfere with the vision. Interestingly,
after two months, the hydrogel had not moved from the site at which it
was initially injected.[173] In addition, it is essential to highlight that
opaque FDA approved implants are successfully used in the clinic to
treat ocular diseases.[303] However, it is clear that bulky opaque ma-
terials/implants are not ideal for intravitreal drug delivery as they
could prevent light from reaching the retina. Therefore, since that hy-
drogels are swellable materials, it is important that opaque gels do not
obscure the vision by increasing in size due to swelling and/or de-
gradation after intravitreal implantation. Moreover, small opaque ma-
terials should not be injected in the middle of the vitreous body to
prevent any discomfort for the patient.
The viscosity of polymeric solutions during injection needs to be
considered when developing an injectable in-situ, forming hydrogel as
the needle diameter used for intraocular delivery is very small (~22-
31G).[165,284] Generally, hydrogels developed for ocular delivery
have a relatively high polymeric concentration to achieve extended-
release profiles. This high concentration, in turn, may render the in-
jectable solution very viscous and, therefore, do not allow the use of
small needles. For this reason, research has been focused on hydrogels
that have low initial viscosity, which can increase quickly upon a sol-gel
transition at the site of injection. The sol-gel change should occur
shortly after injection but not instantaneously to prevent gelation and
thus clogging in the needle during the injection procedure.
4.3. Sterilization methods, safety issues, and industrial production
The sterilization methods and safety issues are parameters that need
to be taken into consideration for the design and development of in-
traocular hydrogels that aim to receive approval by registration au-
thorities. The sterilization process of polymeric biomaterials is often
challenging, as many sterilization methods have shown to affect the
properties of biodegradable polymers profoundly.[304] The steriliza-
tion processes among which radiation, chemical sterilization and ex-
posure to high temperatures can cause unwanted polymer degradation
and structural changes.[304–306] Also, undesirable effects of the ap-
plied sterilization method on the loaded proteins may be a significant
issue. Therefore, preferred sterilization methods may differ depending
on the polymer/hydrogel composition and drug properties. Im-
portantly, aseptic production technologies and sterile filtration re-
present an attractive method to pharmaceutically produce sterile hy-
drogel products. Saher et al. used thermosensitive (poloxamer 407 and
188) and ion-activated Gelrite polymers (phytagel) to formulate an
ocular in-situ forming gel. The authors concluded that for this system,
sterile filtration via a 0.22-μm membrane filter was a more effective
sterilization method than gamma sterilization.[307]
Hydrogel degradability is a crucial issue to consider when devel-
oping intraocular hydrogel formulations. As previously discussed, hy-
drogels can be engineered to degrade by enzymatic hydrolysis, photo-
lytic cleavage, via ester hydrolysis or a combination of these
mechanisms with different degradation rates, depending on the desired
drug release rate and specific application. Hydrogels are generally de-
signed to degrade into non-toxic soluble products, which can be either
be metabolized and eliminated from the body. It should be mentioned
that, so far, there are very limited studies describing the long term in
vivo hydrogel degradation in vitreous. However, during material design,
it is essential to scrutinize the elimination pathways of molecules used
or generated during hydrogel chemical crosslinking or degradation
(such as unreacted monomer, initiator, reactive groups and
crosslinkers), as such molecules could cause local or systemic toxicity.
For example, photo-initiators, such as 2,2-dimethoxy-2-phenyl-acet-
ophenone (mentioned in section 3.4.1), can potentially be cytotoxic and
they produce potentially harmful free radicals.[308] Unreacted func-
tional groups (e.g. maleimide, thiols) and polymer fragments can leak
out of the hydrogel network during swelling and degradation to the
surrounding tissues triggering undesired side reactions. [309] To
overcome these issues, research should focus on crosslinking strategies
that do not require toxic catalysts and do not generate toxic by-products
(e.g. copper-free strain-promoted azide-alkyne cycloaddition[201], in-
verse-electron demand Diels-alder[310] and Staudinger ligation).
[295,311] Ideally, hydrogel network degradation should generate bio-
logically inert molecules or polymer fragments that can be quickly
eliminated from the eye and body. (e.g. small and hydrophilic frag-
ments with non-reactive functional groups).
In addition, more information on intravitreal clearance of molecules
with different properties (such as size, charge and composition) in re-
levant animal models that can allow animal-to-human translation are
considered valuable for the development of intravitreal dosage forms.
In 2015, Del Amo et al. analyzed data found in the literature on in-
travitreal pharmacokinetics in rabbits and humans and concluded that
the rabbit animal model could provide a useful prediction for clinical
translation.[312] This study did not evaluate disease state effects,
which might complement the understanding of intravitreal pharmaco-
kinetics.
Furthermore, other safety issues that are to be considered when
designing injectable in-situ forming hydrogels for prolonged intraocular
release of biotherapeutics are IOP and hydrogel toxicity. As mentioned,
hydrogels are swellable materials, and it is important that the swelling
properties of the designed hydrogels do not cause IOP. Therefore, ef-
forts should be made to systematically study the correlation between
hydrogel swelling ratios and the risk of IOP, as not much information
has been reported until now. The toxicity of hydrogels to ocular tissues
has been tested both in animal models (rat, mouse, rabbit) and cell
models (e.g. RPE cell; L-929 cells) (Table 3). Overall, no significant
toxicity has been observed using these models for many hydrogel for-
mulations. However, efforts should be made to evaluate the cyto-
compatibility of new polymer building blocks and formulations also on
other ocular cells, especially those that are relatively in close proximity
to the vitreous cavity (e.g. Ganglion cells, Muller cell, and photo-
receptors). Yu et al. demonstrated that an HA-VS/Dex-SH hydrogel was
relatively safe using in vitro cytocompatibility tests on ARPE19 cells and
"in vivo" compatibility on female New Zealand White rabbit’s eye.
Further, IOP measurement, ophthalmoscope, full-field electro-
retinography (ERG), and histological studies showed that the system
was compatible with the rabbit’s eye after ~ 3 months of evaluation.
[165] Other in vitro and in vivo safety tests of different intraocular hy-
drogel formulations suggest that many of them are potentially safe for
intraocular applications.[177,241,284,287] Nevertheless, long term
safety on the human eye has to be investigated.
Furthermore, despite the promising preclinical results and the eco-
nomic potential of intravitreal hydrogels, issues in industrial scale-up
and production need to be adequately tackled in the development stage.
The manufacturing process and quality control should all match with
the standards of GMP and Pharmacopeia. Unfortunately, during the
early preclinical research, these crucial aspects are generally in-
sufficiently studied as a result of lacking information in the literature
regarding scalability and process development toward GMP manu-
facturing of hydrogels for ocular applications. The novelty of the ap-
proach might be the primary reason for this gap in knowledge. This
challenge is even more prominent due to the complex chemistry re-
quired to design in situ forming hydrogel for intravitreal protein de-
livery. The production of polymeric hydrogels is generally accom-
plished by polymerization of different monomers (mainly hydrophilic)
or by modification or functionalization of existing polymers (natural or
synthetic). In some cases, multiple synthetic steps are required first to
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produce the monomers or the functional linkers and then proceed with
polymerization or functionalization and crosslinking. This long and
complicated synthesis route might limit industrial production as it may
not be cost-effective. Unfortunately, another critical challenge that
needs to be addressed is the issue of batch-to-batch variation seen on
the polymer synthesis (e.g. molecular weight, degree of substitution of
functional groups) and hydrogel crosslinking density which could then
cause unpredictable release profiles. Finally, it is essential to consider
that intraocular polymer depot systems can potentially be contaminated
with endotoxins during the polymer production or packaging processes.
According to FDA guidelines (issued in 2015, "endotoxin testing re-
commendations for single-use intraocular ophthalmic devices”), the
recommended endotoxin limit for ophthalmic devices is ≤0.2 EU/mL
for the anterior and posterior segment of the eye.[313] Endotoxins
cannot be easily removed after contamination, and thus the re-
commended limit value should be taken into account in starting ma-
terials and processes. Natural polymer materials may be more prone to
endotoxin contamination when compared to synthetic polymers due to
difficulties in optimal purification from natural sources.
5. Conclusion and perspectives
Intraocular drug delivery is an important challenge, considering
that retinal diseases are the leading cause of visual impairment
worldwide. So far, the treatments with therapeutic proteins still face
significant limitations, including frequent intraocular injections, related
adverse effects, relatively high clearance and high costs of the treat-
ments. The efficiency of intraocularly injected proteins such as bev-
acizumab, ranibizumab, aflibercept and infliximab has been shown, but
despite the clinical successes, sustaining sufficient concentrations in the
target tissue for an extended period is still challenging. This review
describes the ideal features of hydrogels that could solve these major
limitations. In the last years, tremendous efforts have been made to
develop injectable, fast gelling, biocompatible and biodegradable gels.
However, challenges regarding initial gel viscosity, hydrogel turbidity,
crosslinking strategies, sterilization procedures, storage conditions and
long-term intraocular safety need to be addressed by formulation sci-
entists and ophthalmologists to facilitate their clinical translation.
The next-generation of intravitreal hydrogels for improved sus-
tained protein delivery should move towards biorthogonal crosslinking
to preserve the stability of the encapsulated bioactive and also improve
the safety profile of the used materials. Furthermore, the continuous
down-regulation of VEGF in the eye due to the prolonged release of
anti-VEGF from the hydrogel depot, might, in the long run, cause un-
desired side effects. Therefore, the next generation of hydrogels depot
ideally should focus on disease state triggered sustained release of anti-
VEGF so that the depot will release the drug only when there is an up-
regulation of the growth factor. Hydrogel depots that provide co-de-
livery of low molecular weight drugs (e.g. anti-inflammatory corticos-
teroids) together with therapeutic proteins for a synergic effect might
offer an attractive platform for intraocular therapy. Overall, from a
clinical standpoint, injectable hydrogels have shown to be attractive
tools for sustained protein delivery to the back of the eye. Their ad-
ministration is similar to the current clinical procedures for intravitreal
injections of anti-VEGF, but less frequent injections are potentially
needed. Therefore, hydrogels may represent a useful tool to solve the
unmet needs in intraocular protein delivery to the retina in the near
future.
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